ITRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Iterum Therapeutics PLC (ITRM) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock faces significant challenges, including a potential delisting from Nasdaq, financial instability, and lack of positive trading signals. Additionally, there are no recent positive news or catalysts to support a bullish outlook.
The MACD is positive and expanding, which is a mild bullish indicator. However, the RSI is neutral at 52.919, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 0.178 and 0.185, while support levels are at 0.155 and 0.148. Overall, the technical indicators suggest a weak or uncertain trend.
NULL identified. No recent news or significant trading trends to support a positive outlook.
The company is at risk of being delisted from Nasdaq due to non-compliance with listing requirements. Additionally, the company may face challenges raising capital in Q2 2026 due to its distressed valuation. Analysts have downgraded the stock to Hold, citing these concerns.
In Q3 2025, revenue remained flat at $390,000 YoY. Net income improved to -$8,979,000, up 47.34% YoY, but the company is still operating at a significant loss. EPS dropped to -0.2, down 33.33% YoY, indicating worsening shareholder returns. Gross margin remained flat at 5.38%. Overall, the financials show no significant growth and highlight ongoing financial struggles.
Maxim analyst downgraded the stock to Hold from Buy, citing risks of delisting and challenges in raising capital. This reflects a bearish sentiment among analysts.
